Binge-Eating Disorder, Obesity
Conditions
Brief summary
This study will test the effectiveness of lisdexamfetamine (LDX) medication as a maintenance therapy for the treatment of binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, LDX medication results in superior maintenance and longer-term outcomes compared with placebo.
Detailed description
Obesity is a heterogeneous problem and research has highlighted the particular significance of a subgroup with binge-eating disorder (BED), the most prevalent formal eating disorder. Improved treatments for patients with obesity and BED are needed that can produce sustained clinical outcomes and promote weight loss. This study (maintenance stage) RCT will provide findings from a controlled test, amongst responders to acute treatments, whether LDX medication results in superior maintenance and longer-term outcomes than placebo. This is one of the few RCTs for BED of medication with follow-up after medication discontinuation.
Interventions
DRUGLisdexamfetamine Dimesylate
Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
DRUGPlacebo
Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* 18 to 64 years old * Meets DSM-5 criteria for binge-eating disorder * BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and \<50 * Medically cleared as determined by EKG and medical record review * Available for the duration of the treatment and follow-up (18 months) * Read, comprehend, and write English at a sufficient level to complete study-related materials * Able to travel to study location (New Haven, CT) for weekly visits
Exclusion criteria
* Previous history of problems with LDX or other stimulants * Current psychostimulant use or use of any medication for ADHD * Current use of study medications: LDX (Vyvanse), Bupropion (Wellbutrin, Zyban), Naltrexone, or Contrave * History of congenital heart disease, known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, cerebrovascular pathology including stroke, exertional chest pain, uncontrolled high blood pressure, and other serious heart problems. * History of severe renal, hepatic, neurological, or chronic pulmonary disease or other serious, unstable medical disorder. * Current uncontrolled hypertension * Current uncontrolled type I or II diabetes mellitus * Current uncontrolled thyroid illness * Gallbladder disease * Co-occurring severe mental illness requiring hospitalization or intensive treatment * Endorses current active suicidal or homicidal ideation with intent or plan * History or current alcohol or substance use disorder (smoking is not exclusionary) * Predisposition to seizures * History of anorexia nervosa or bulimia nervosa, or currently regularly self-inducing vomiting * Currently taking MAOI, SSRI or strong inhibitors of CYP2D6 * History of allergy or sensitivity to the study medication or stimulant medications * Current use of medications contraindicated with the study medications * Currently breast feeding or pregnant, or not willing to use reliable form of contraception * Currently taking opioid pain medications or drugs * Currently using effective treatment (evidence-based therapeutic or psychopharmacologic) for eating and/or weight loss * Currently participating in another clinical study in which the participant is or will be exposed to an investigational or a non-investigational drug or device * Medical status judged by study physician as contraindication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Binge-Eating Relapse | 12 weeks | Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Binge-Eating Frequency | From baseline interview at study enrollment to 3 months after the 12-week treatment | Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month. |
| Change in Eating-Disorder Psychopathology (Continuous) | From baseline interview at study enrollment to 3 months after the 12-week treatment | Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology). |
| Change in Depressive Symptoms | From baseline interview at study enrollment to 3 months after the 12-week treatment | Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms). |
| Percent Change in Weight | From baseline interview at study enrollment to 3 months after the 12-week treatment | Negative values indicate weight loss and positive values indicate weight gain. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LDX (Lisdexamfetamine Dimesylate) Lisdexamfetamine Dimesylate: Participants randomly assigned to this arm will receive 12 weeks of LDX medication. | 32 |
| Placebo Placebo: Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo. | 29 |
| Total | 61 |
Baseline characteristics
| Characteristic | LDX (Lisdexamfetamine Dimesylate) | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 42.97 years STANDARD_DEVIATION 11.38 | 44.33 years STANDARD_DEVIATION 10.86 | 45.83 years STANDARD_DEVIATION 10.24 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants | 12 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants | 49 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 9 Participants | 6 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) White | 25 Participants | 46 Participants | 21 Participants |
| Region of Enrollment United States | 32 participants | 61 participants | 29 participants |
| Sex: Female, Male Female | 27 Participants | 51 Participants | 24 Participants |
| Sex: Female, Male Male | 5 Participants | 10 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 29 |
| other Total, other adverse events | 13 / 32 | 6 / 29 |
| serious Total, serious adverse events | 0 / 32 | 0 / 29 |
Outcome results
Primary
Binge-Eating Relapse
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Binge-Eating Relapse | 3 Participants |
| Placebo | Binge-Eating Relapse | 5 Participants |
Primary
Binge-Eating Relapse
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
Time frame: 6-month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Binge-Eating Relapse | 6 Participants |
| Placebo | Binge-Eating Relapse | 6 Participants |
Primary
Binge-Eating Relapse
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
Time frame: 12 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Binge-Eating Relapse | 3 Participants |
| Placebo | Binge-Eating Relapse | 2 Participants |
Secondary
Change in Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
Time frame: From post-treatment to the 6-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Binge-Eating Frequency | 2.45 episodes per the past 28 days | Standard Deviation 5.39 |
| Placebo | Change in Binge-Eating Frequency | 1.00 episodes per the past 28 days | Standard Deviation 6.86 |
Secondary
Change in Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
Time frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Binge-Eating Frequency | 1.33 episodes per the past 28 days | Standard Deviation 5.82 |
| Placebo | Change in Binge-Eating Frequency | 1.61 episodes per the past 28 days | Standard Deviation 4.37 |
Secondary
Change in Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
Time frame: From post-treatment to the 12-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Binge-Eating Frequency | 1.28 episodes per the past 28 days | Standard Deviation 4.14 |
| Placebo | Change in Binge-Eating Frequency | -.09 episodes per the past 28 days | Standard Deviation 2.29 |
Secondary
Change in Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Depressive Symptoms | 2.16 score on a scale | Standard Deviation 5.27 |
| Placebo | Change in Depressive Symptoms | 0.18 score on a scale | Standard Deviation 7.07 |
Secondary
Change in Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time frame: From post-treatment to the 6-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Depressive Symptoms | 1.12 score on a scale | Standard Deviation 5.63 |
| Placebo | Change in Depressive Symptoms | 3.35 score on a scale | Standard Deviation 9.14 |
Secondary
Change in Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time frame: From post-treatment to the 12-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Depressive Symptoms | 0.07 score on a scale | Standard Deviation 6.98 |
| Placebo | Change in Depressive Symptoms | 1.71 score on a scale | Standard Deviation 4.95 |
Secondary
Change in Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From post-treatment to the 6-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Eating-Disorder Psychopathology (Continuous) | 0.23 score on a scale | Standard Deviation 0.95 |
| Placebo | Change in Eating-Disorder Psychopathology (Continuous) | 0.17 score on a scale | Standard Deviation 0.6 |
Secondary
Change in Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Eating-Disorder Psychopathology (Continuous) | -0.05 score on a scale | Standard Deviation 0.77 |
| Placebo | Change in Eating-Disorder Psychopathology (Continuous) | 0.50 score on a scale | Standard Deviation 0.64 |
Secondary
Change in Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From post-treatment to the 12-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Change in Eating-Disorder Psychopathology (Continuous) | 0.09 score on a scale | Standard Deviation 0.83 |
| Placebo | Change in Eating-Disorder Psychopathology (Continuous) | -0.07 score on a scale | Standard Deviation 0.59 |
Secondary
Percent Change in Weight
Negative values indicate weight loss and positive values indicate weight gain.
Time frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Percent Change in Weight | -2.39 percent change | Standard Deviation 2.95 |
| Placebo | Percent Change in Weight | 2.25 percent change | Standard Deviation 2.51 |
Secondary
Percent Change in Weight
Negative values indicate weight loss and positive values indicate weight gain.
Time frame: From post-treatment to the 6-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Percent Change in Weight | 2.54 percent change | Standard Deviation 6.32 |
| Placebo | Percent Change in Weight | 0.45 percent change | Standard Deviation 3.04 |
Secondary
Percent Change in Weight
Negative values indicate weight loss and positive values indicate weight gain.
Time frame: From post-treatment to the 12-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LDX (Lisdexamfetamine Dimesylate) | Percent Change in Weight | 4.04 percent change | Standard Deviation 6.58 |
| Placebo | Percent Change in Weight | 2.67 percent change | Standard Deviation 5.73 |